Toripalimab Set For ASCO Buzz With New Nasopharyngeal Data

First-Line PFS Improvements

Junshi and Coherus's PD-1 was already gaining attention for a particularly difficult cancer type even before the meeting, but new data add to its luster ahead of a potential US approval. 

NPC
Toripalimab Provides New Hope For First-Line NPC • Source: Alamy

Some of the most closely watched results at the American Society of Clinical Oncology (ASCO) meeting this year are those from Chinese firm Shanghai Junshi Biosciences Co., Ltd. and its partner Coherus BioSciences, Inc. for the anti-PD-1 antibody toripalimab in first-line nasopharyngeal carcinoma (NPC).

The read-outs are significant for multiple reasons: it’s a high-need indication with few treatment options; they may lead to a...

More from Anticancer

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

More from Therapy Areas